![site logo](https://d12v9rtnomnebu.cloudfront.net/logo/printer_friendly/biopharmadive.jpg)
The BioPharma Dive Awards for 2020
Vaccine developers and COVID-19 researchers took center stage in a year turned upside down by the pandemic.
![The BioPharma Dive Awards for 2020](/imgproxy/KIm_B15TD1hoiw7cJWKwsArtu0ND_b_iV7uS54ysTj4/g:ce/rs:fill:1200:675:1/bG9jYWw6Ly8vZGl2ZWltYWdlL0Jpb1BoYXJtYV9EQV8yMDIwLXYyX21OOTloRGIuanBn.webp)
-
Defying expectations, BioNTech and Moderna each designed and developed highly effective coronavirus shots far faster than previously considered possible. Read more ➔
-
A billion-dollar deal with Merck followed quick approvals for the company's second and third drugs, pushing Seagen's market value to over $30 billion. Read more ➔
-
The U.K.'s RECOVERY trial proved a cheap steroid could keep COVID-19 patients from dying, and showed two other widely considered drugs didn't work — crucial findings in a sprawling, global hunt for coronavirus treatments. Read more ➔